Compare NNNN & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNNN | JRI |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Germany | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.8M | 356.8M |
| IPO Year | N/A | N/A |
| Metric | NNNN | JRI |
|---|---|---|
| Price | $9.25 | $12.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.6K | ★ 105.9K |
| Earning Date | 04-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.30 | $11.67 |
| 52 Week High | $54.90 | $14.37 |
| Indicator | NNNN | JRI |
|---|---|---|
| Relative Strength Index (RSI) | 37.56 | 45.28 |
| Support Level | $8.30 | $12.76 |
| Resistance Level | $29.98 | $13.11 |
| Average True Range (ATR) | 1.31 | 0.15 |
| MACD | 0.58 | -0.03 |
| Stochastic Oscillator | 33.89 | 11.46 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Nuveen Real Asset Income and Growth Fund is a closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.